Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes

Diabetes Care. 2007 Sep;30(9):2242-4. doi: 10.2337/dc07-0341. Epub 2007 Jun 22.
No abstract available

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / therapy*
  • Combined Modality Therapy
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / therapy*
  • Exercise Therapy*
  • Female
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Male
  • Middle Aged
  • Obesity / complications
  • Risk Factors
  • Rosiglitazone
  • Thiazolidinediones / therapeutic use*

Substances

  • Hypoglycemic Agents
  • Thiazolidinediones
  • Rosiglitazone

Associated data

  • ClinicalTrials.gov/NCT00306176